Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | CDC25B | P30305 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 4/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | TACR2 | P21452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15437489 | 0.90 | TACR1 (0.34) | PTPN1CDC25BTACR1PDPK1MTOR | |
| SCHEMBL15437547 | 0.89 | MEN1 (0.35) | PTPN1CDC25BTACR1PDPK1MTOR | |
| SCHEMBL15437485 | 0.89 | MEN1 (0.35) | PTPN1CDC25BTACR1PDPK1MTOR | |
| SCHEMBL15437647 | 0.89 | MEN1 (0.35) | PTPN1CDC25BTACR1PDPK1MTOR | |
| SCHEMBL15437693 | 0.84 | HTT (0.34) | PTPN1CDC25BTACR1PDPK1MTOR | |
| SCHEMBL15437540 | 0.82 | PDPK1 (0.34) | PDPK1MTOR | |
| SCHEMBL17170426 | 0.81 | SLC6A2 (0.39) | PDPK1MTORSLC6A2TACR2 | |
| SCHEMBL15437496 | 0.81 | SLC6A2 (0.39) | PDPK1MTORSLC6A2TACR2 | |
| SCHEMBL19682304 | 0.80 | PDPK1 (0.36) | TACR1PDPK1MTORSLC6A2 | |
| SCHEMBL15437563 | 0.80 | HTT (0.35) | PTPN1CDC25BHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024576-A1 | HEPTOSE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | LABORATOIRE BIODIM (FR) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024576-A1 | HEPTOSE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | GALE, G6PD, UGDH | PTPN1 1197/4885CDC25B 1690/4885TACR1 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.